Helus Pharma Inc Dossier
Qualitative Analysis
Business overview
Helus Pharma Inc. (NASDAQ: HELP; Cboe Canada: HELP), formerly operating as Cybin Inc., is a clinical-stage biopharmaceutical company dedicated to developing novel serotonergic agonists (NSAs). These synthetic molecules are engineered to target specific serotonin receptors (primarily 5-HT2A) to promote neuroplasticity and address major unmet needs in mental health care. The company's lead clinical programs are HLP003, a deuterated oral formulation of psilocin under development as an adjunctive treatment for major depressive disorder (MDD), and HLP004, a deuterated dimethyltryptamine (DMT) formulation administered intramuscularly for generalized anxiety disorder (GAD).
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Rebranded from Cybin Inc. to Helus Pharma and transferred the company's U.S. listing from the NYSE American to the Nasdaq Global Market.
Expected impact: Repositioned the company from a discovery-stage entity to a commercial-ready pharmaceutical organization, enhancing market visibility and liquidity.
Advancing the clinical development of lead candidate HLP003 through the multi-study PARADIGM program, which includes the APPROACH trial, the EMBRACE pivotal study, and the EXTEND long-term safety rollover study.
Expected impact: Aims to establish a paradigm shift in efficacy and durability for the adjunctive treatment of major depressive disorder (MDD).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Small Pharma, the developer of SPL026 (DMT) and SPL028 (deuterated DMT), to expand the company's clinical pipeline of psychedelic-based therapeutics.
Financial impact: Significantly expanded the company's patent portfolio to over 100 granted patents and 250 pending applications globally.
Strategic Partnerships
Collaborating to support clinical trial recruitment for the PARADIGM HLP003 Phase 3 program, specifically focusing on expanding mental health awareness and access within the veteran community [1.2.3].
Terms: Not publicly disclosed